<p>10x Genomics（納斯達克代碼：TXG - 獲取免費報告）週四交易中股價下跌了 6.7%。該股最低交易價格為 16.40 美元，最後交易價格為 16.3510 美元。交易期間共成交 462,460 股，較平均交易量 3,185,433 股下降了 85%。該股此前收盤價為 17.53 美元。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>戰略買入點亮這隻生物科技股票：是時候投資了嗎？</li>
</ul>
<p>多位研究分析師最近對 TXG 股票發表了看法。Weiss Ratings 在週一的研究報告中重新發布了對 10x Genomics 的 “賣出（d-）” 評級。巴克萊將 10x Genomics 的目標價格從 15.00 美元上調至 17.00 美元，並在 11 月 7 日的研究報告中給予該公司 “增持” 評級。華爾街 Zen 在 11 月 15 日的研究報告中將 10x Genomics 的評級從 “買入” 下調至 “持有”。花旗集團在週四的研究報告中重申了對 10x Genomics 的 “中性” 評級。最後，瑞銀集團在 11 月 7 日的報告中將 10x Genomics 的目標價格從 13.00 美元上調至 14.00 美元，並給予該公司 “中性” 評級。四位投資分析師對該股給予 “買入” 評級，十位分析師給予 “持有” 評級，兩位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股目前的共識評級為 “持有”，平均目標價格為 15.12 美元。</p>
<p><strong>查看我們關於 TXG 的最新報告</strong></p>
<h2>10x Genomics 股票表現</h2>
<p>該公司的 50 日移動平均線為 14.93 美元，200 日移動平均線為 13.19 美元。該公司的市值為 21 億美元，市盈率為-26.76，貝塔值為 2.15。</p>
<p>10x Genomics（納斯達克代碼：TXG - 獲取免費報告）於 11 月 6 日（週四）發佈了季度財報。該公司報告本季度每股收益為（0.22 美元），超出市場共識預期的（0.27 美元）0.05 美元。10x Genomics 的淨利潤率為-11.89%，股本回報率為-11.50%。該公司本季度的收入為 1.49 億美元，而分析師預期為 1.425 億美元。去年同期，該公司每股收益為（0.30 美元）。該公司的季度收入較去年同期下降了 1.7%。整體來看，分析師預計 10x Genomics 在本財年將發佈-1.43 的每股收益。</p>
<h2>內部人士下注</h2>
<p>在相關消息中，首席財務官 Adam Taich 於 11 月 24 日（週一）出售了 11,888 股該股票，交易價格為 19.00 美元，總交易額為 225,872.00 美元。交易完成後，首席財務官直接持有該公司 297,385 股，價值約為 5,650,315 美元。此交易代表其持股比例下降了 3.84%。該交易已在證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。此外，內部人士 Benjamin J. Hindson 於 11 月 24 日（週一）出售了 8,283 股 10x Genomics 股票，交易價格為 19.00 美元，總價值為 157,377.00 美元。交易完成後，該內部人士直接持有 432,605 股，價值約為 8,219,495 美元。這代表其持股比例下降了 1.88%。有關此交易的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士共出售了價值 635,208 美元的 33,432 股公司股票。公司內部人士持有公司股票的 9.39%。</p>
<h2>10x Genomics 的機構交易</h2>
<p>多位大型投資者最近增加或減少了對該公司的持股。瑞銀資產管理公司（UBS AM）在第一季度將其在 10x Genomics 的持股比例提高了 235.6%。瑞銀資產管理公司現在擁有 7,103,768 股該公司股票，價值 62,016,000 美元，此前在此期間又購買了 4,987,195 股。千禧管理公司（Millennium Management LLC）在第一季度將其在 10x Genomics 的持股比例提高了 434.5%。千禧管理公司現在擁有 5,377,492 股該公司股票，價值 46,946,000 美元，此前在上個季度又收購了 4,371,327 股。AQR 資本管理公司（AQR Capital Management LLC）在第二季度將其在 10x Genomics 的持股比例提高了 241.3%。AQR 資本管理公司現在擁有 4,137,801 股該公司股票，價值 47,916,000 美元，此前在上個季度又收購了 2,925,372 股。威靈頓管理集團（Wellington Management Group LLP）在第三季度將其在 10x Genomics 的持股比例提高了 126.6%。威靈頓管理集團現在擁有 4,285,628 股該公司股票，價值 50,099,000 美元，此前在此期間又收購了 2,394,355 股。最後，Quantinno 資本管理公司（Quantinno Capital Management LP）在第二季度將其在 10x Genomics 的持股比例提高了 207.2%。Quantinno 資本管理公司現在擁有 2,233,526 股該公司股票，價值 25,864,000 美元，此前在上個季度又購買了 1,506,530 股。機構投資者和對沖基金持有該公司 84.68% 的股票。</p>
<h2>10x Genomics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>10x Genomics, Inc 是一家生命科學技術公司，開發和銷售用於分析生物系統的儀器、耗材和軟件，業務覆蓋美洲、歐洲、中東、非洲、中國和亞太地區。該公司提供鉻、鉻連接和鉻控制儀器、微流控芯片、載玻片、試劑和其他耗材產品。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 10x Genomics</li>
<li>安靜期到期的解釋</li>
<li>量子艦隊：投資新的量子標準</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>AST SpaceMobile 為下週的 BlueBird 6 發射做好準備</li>
<li>特殊目的收購公司（SPAC）你需要知道的事項</li>
<li>人工智能與量子技術的下一個贏家：2026 年值得關注的三隻小盤股</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 10x Genomics 嗎？</h2>
<p>在你考慮 10x Genomics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 10x Genomics 並不在名單上。</p>
<p>雖然 10x Genomics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>10X Genomics（納斯達克代碼：TXG）股價下跌 6.7%，至 16.3510 美元，交易量為 462,460 股，較平均水平下降 85%。分析師的評級意見不一：Weiss Ratings - 賣出，巴克萊 - 超配，華爾街禪 - 持有，花旗集團和瑞銀 - 中性。該公司報告的第三季度收益好於預期，但淨利潤率和股本回報率均為負值。內部人士近期出售了股份。機構投資者顯著增加了他們的持股比例</p>

<p>10x Genomics (NASDAQ:TXG - Get Free Report)'s share price fell 6.7% during trading on Thursday . The stock traded as low as $16.40 and last traded at $16.3510. 462,460 shares traded hands during trading, a decline of 85% from the average session volume of 3,185,433 shares. The stock had previously closed at $17.53.</p>
<div class="lb-trans"><p>10x Genomics（納斯達克代碼：TXG - 獲取免費報告）週四交易中股價下跌了 6.7%。該股最低交易價格為 16.40 美元，最後交易價格為 16.3510 美元。交易期間共成交 462,460 股，較平均交易量 3,185,433 股下降了 85%。該股此前收盤價為 17.53 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>戰略買入點亮這隻生物科技股票：是時候投資了嗎？</li>
</ul>
</div><p>A number of research analysts have recently weighed in on TXG shares. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of 10x Genomics in a research note on Monday. Barclays increased their target price on 10x Genomics from $15.00 to $17.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, November 7th. Wall Street Zen lowered 10x Genomics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 15th. Citigroup reiterated a &#34;neutral&#34; rating on shares of 10x Genomics in a research report on Thursday. Finally, UBS Group boosted their price objective on shares of 10x Genomics from $13.00 to $14.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and an average target price of $15.12.</p>
<div class="lb-trans"><p>多位研究分析師最近對 TXG 股票發表了看法。Weiss Ratings 在週一的研究報告中重新發布了對 10x Genomics 的 “賣出（d-）” 評級。巴克萊將 10x Genomics 的目標價格從 15.00 美元上調至 17.00 美元，並在 11 月 7 日的研究報告中給予該公司 “增持” 評級。華爾街 Zen 在 11 月 15 日的研究報告中將 10x Genomics 的評級從 “買入” 下調至 “持有”。花旗集團在週四的研究報告中重申了對 10x Genomics 的 “中性” 評級。最後，瑞銀集團在 11 月 7 日的報告中將 10x Genomics 的目標價格從 13.00 美元上調至 14.00 美元，並給予該公司 “中性” 評級。四位投資分析師對該股給予 “買入” 評級，十位分析師給予 “持有” 評級，兩位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股目前的共識評級為 “持有”，平均目標價格為 15.12 美元。</p>
</div><p><strong>Check Out Our Latest Report on TXG</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 TXG 的最新報告</strong></p>
</div><h2>10x Genomics Stock Performance</h2>
<div class="lb-trans"><h2>10x Genomics 股票表現</h2>
</div><p>The company has a 50-day moving average of $14.93 and a 200-day moving average of $13.19. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -26.76 and a beta of 2.15.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 14.93 美元，200 日移動平均線為 13.19 美元。該公司的市值為 21 億美元，市盈率為-26.76，貝塔值為 2.15。</p>
</div><p>10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company had revenue of $149.00 million during the quarter, compared to analysts' expectations of $142.50 million. During the same quarter in the prior year, the company earned ($0.30) earnings per share. The business's quarterly revenue was down 1.7% compared to the same quarter last year. As a group, analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>10x Genomics（納斯達克代碼：TXG - 獲取免費報告）於 11 月 6 日（週四）發佈了季度財報。該公司報告本季度每股收益為（0.22 美元），超出市場共識預期的（0.27 美元）0.05 美元。10x Genomics 的淨利潤率為-11.89%，股本回報率為-11.50%。該公司本季度的收入為 1.49 億美元，而分析師預期為 1.425 億美元。去年同期，該公司每股收益為（0.30 美元）。該公司的季度收入較去年同期下降了 1.7%。整體來看，分析師預計 10x Genomics 在本財年將發佈-1.43 的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In related news, CFO Adam Taich sold 11,888 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $225,872.00. Following the completion of the transaction, the chief financial officer directly owned 297,385 shares in the company, valued at approximately $5,650,315. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 8,283 shares of 10x Genomics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $157,377.00. Following the completion of the sale, the insider directly owned 432,605 shares in the company, valued at approximately $8,219,495. This represents a 1.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 33,432 shares of company stock worth $635,208. Corporate insiders own 9.39% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Adam Taich 於 11 月 24 日（週一）出售了 11,888 股該股票，交易價格為 19.00 美元，總交易額為 225,872.00 美元。交易完成後，首席財務官直接持有該公司 297,385 股，價值約為 5,650,315 美元。此交易代表其持股比例下降了 3.84%。該交易已在證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。此外，內部人士 Benjamin J. Hindson 於 11 月 24 日（週一）出售了 8,283 股 10x Genomics 股票，交易價格為 19.00 美元，總價值為 157,377.00 美元。交易完成後，該內部人士直接持有 432,605 股，價值約為 8,219,495 美元。這代表其持股比例下降了 1.88%。有關此交易的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士共出售了價值 635,208 美元的 33,432 股公司股票。公司內部人士持有公司股票的 9.39%。</p>
</div><h2>Institutional Trading of 10x Genomics</h2>
<div class="lb-trans"><h2>10x Genomics 的機構交易</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock worth $62,016,000 after purchasing an additional 4,987,195 shares during the period. Millennium Management LLC lifted its position in 10x Genomics by 434.5% during the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company's stock worth $46,946,000 after acquiring an additional 4,371,327 shares during the last quarter. AQR Capital Management LLC lifted its position in 10x Genomics by 241.3% during the second quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company's stock worth $47,916,000 after acquiring an additional 2,925,372 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of 10x Genomics by 126.6% during the third quarter. Wellington Management Group LLP now owns 4,285,628 shares of the company's stock worth $50,099,000 after acquiring an additional 2,394,355 shares during the period. Finally, Quantinno Capital Management LP grew its position in shares of 10x Genomics by 207.2% in the second quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company's stock valued at $25,864,000 after purchasing an additional 1,506,530 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.</p>
<div class="lb-trans"><p>多位大型投資者最近增加或減少了對該公司的持股。瑞銀資產管理公司（UBS AM）在第一季度將其在 10x Genomics 的持股比例提高了 235.6%。瑞銀資產管理公司現在擁有 7,103,768 股該公司股票，價值 62,016,000 美元，此前在此期間又購買了 4,987,195 股。千禧管理公司（Millennium Management LLC）在第一季度將其在 10x Genomics 的持股比例提高了 434.5%。千禧管理公司現在擁有 5,377,492 股該公司股票，價值 46,946,000 美元，此前在上個季度又收購了 4,371,327 股。AQR 資本管理公司（AQR Capital Management LLC）在第二季度將其在 10x Genomics 的持股比例提高了 241.3%。AQR 資本管理公司現在擁有 4,137,801 股該公司股票，價值 47,916,000 美元，此前在上個季度又收購了 2,925,372 股。威靈頓管理集團（Wellington Management Group LLP）在第三季度將其在 10x Genomics 的持股比例提高了 126.6%。威靈頓管理集團現在擁有 4,285,628 股該公司股票，價值 50,099,000 美元，此前在此期間又收購了 2,394,355 股。最後，Quantinno 資本管理公司（Quantinno Capital Management LP）在第二季度將其在 10x Genomics 的持股比例提高了 207.2%。Quantinno 資本管理公司現在擁有 2,233,526 股該公司股票，價值 25,864,000 美元，此前在上個季度又購買了 1,506,530 股。機構投資者和對沖基金持有該公司 84.68% 的股票。</p>
</div><h2>10x Genomics Company Profile</h2>
<div class="lb-trans"><h2>10x Genomics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.</p>
<div class="lb-trans"><p>10x Genomics, Inc 是一家生命科學技術公司，開發和銷售用於分析生物系統的儀器、耗材和軟件，業務覆蓋美洲、歐洲、中東、非洲、中國和亞太地區。該公司提供鉻、鉻連接和鉻控制儀器、微流控芯片、載玻片、試劑和其他耗材產品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than 10x Genomics</li>
<li>Quiet Period Expirations Explained</li>
<li>The Quantum Fleet: Investing in the New Quantum Standard</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>AST SpaceMobile Gears Up for Its BlueBird 6 Launch Next Week</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>AI &amp; Quantum's Next Big Winners: 3 Small-Cap Stocks to Watch in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 10x Genomics</li>
<li>安靜期到期的解釋</li>
<li>量子艦隊：投資新的量子標準</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>AST SpaceMobile 為下週的 BlueBird 6 發射做好準備</li>
<li>特殊目的收購公司（SPAC）你需要知道的事項</li>
<li>人工智能與量子技術的下一個贏家：2026 年值得關注的三隻小盤股</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in 10x Genomics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 10x Genomics 嗎？</h2>
</div><p>Before you consider 10x Genomics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 10x Genomics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 10x Genomics 並不在名單上。</p>
</div><p>While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 10x Genomics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

10x Genomics（NASDAQ:TXG）股價下跌 6.7% - 現在是賣出的時候嗎？